Optimal initial dose of oral cyclosporine in relation to its toxicities for graft-versus-host disease prophylaxis following reduced-intensity stem cell transplantation in Japanese patients
Authors:
- M KamiMKM Kami
- for the Tokyo Stem Cell Transplantation (SCT) ConsortiumFCfor the Tokyo Stem Cell Transplantation (SCT) Consortium
Open Access
- 4 April 2005
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 35 (11) , 1079-1082
Abstract
Since the introduction of reduced-intensity stem-cell transplantation (RIST), allogeneic stem-cell transplantation has become available for elderly patients. While pharmacokinetics of cyclosporine might differ according to age or other factors, cyclosporine is uniformly started at an oral dose of 6 mg/kg/day. We retrospectively reviewed medical records of 35 patients aged between 32 and 65 (median 52) years who had undergone RIST. Doses of cyclosporine were adjusted to the target blood trough level of 150–250 ng/ml. Cyclosporine dosages were changed in 33 patients (94%). Dose reduction was required in 32 patients because of high blood levels (n=25), renal dysfunction (n=3), hepatic dysfunction (n=2), and hypertension (n=2). Cyclosporine doses were increased in one because of the suboptimal level. The median of the achieved stable doses was 3.1 mg/kg/day (range, 1.0–7.4). Five patients sustained Grade III toxicities according to NCI-CTC version 2.0: renal dysfunction (n=4), hyperbilirubinemia (n=2), and hypertension (n=2). No patients developed grade IV toxicity. There was no statistically significant difference in the frequency and severity of cyclosporine toxicities between patients aged 50 years and above and those below 50 years. The initial oral cyclosporine dose of 6 mg/kg/day was unnecessarily high irrespective of age. The possible overdose of cyclosporine might have aggravated regimen-related toxicities.Keywords
This publication has 13 references indexed in Scilit:
- Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantationTransplantation and Cellular Therapy, 2003
- Estimation of failure probabilities in the presence of competing risks: new representations of old estimatorsStatistics in Medicine, 1999
- Cyclosporin pharmacokinetics in the elderly.Drugs & Aging, 1999
- Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantationTransplantation and Cellular Therapy, 1998
- Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic DiseasesBlood, 1998
- Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantationBone Marrow Transplantation, 1997
- A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT)Bone Marrow Transplantation, 1997
- Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions*Clinical Pharmacology & Therapeutics, 1997
- Comparison of a Monoclonal Antibody Fluorescent Polarization Immunoassay with Monoclonal Antibody Radioimmunoassay for Cyclosporin Determination in Whole BloodTherapeutic Drug Monitoring, 1992
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986